Genscript Biotech Earnings Estimate
Genscript Biotech Earnings per Share Projection vs Actual
About Genscript Biotech Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Genscript Biotech earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Genscript Biotech estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Genscript Biotech fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.